ADVM Adverum Biotechnologies
- 7.5200
- -0.6500-7.96%
Adverum Biotechnologies News
Strong Phase 2 Results and Favorable Safety Profile Justify Buy Rating for Adverum Biotechnologies
More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the
Express News | Chardan Capital Maintains Buy on Adverum Biotechnologies, Adjusts Price Target To $40 ((Reverse Stock Split 1:10))
Adverum Biotechnologies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/18/2024 322.83% Chardan Capital $4 → $40 Maintains Buy 06/25/2024 164.27% Oppenheimer → $25 Initiates
Chardan Research Adjusts Adverum Biotechnologies' PT to $40 From $4, Maintains Buy Rating
Adverum Biotechnologies (ADVM) has an average rating of buy and price targets ranging from $15 to $60, according to analysts by Capital IQ.Price: 8.10, Change: -0.68, Percent Change: -7.74
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $23
Truist Financial analyst Joon Lee maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate of 52.8%
Adverum Biotechnologies' Promising AMD Treatment Advances
Adverum Releases Interim Data From Gene Therapy Study For Blindness Disorder, Prepares For Pivotal Study
Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD).The 26-week interim analysis was
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for
Adverum Biotechnologies Shares Rise As Eye Disease Treatment Study Advances
By Michael Susin Adverum Biotechnologies shares were higher early Wednesday after the company said that its therapy for wet age-related macular degeneration was selected for a late-stage study.
Adverum Reports Positive Interim Results in Study of Investigational Wet AMD Drug
Adverum Biotechnologies (ADVM) said Wednesday that a 26-week interim analysis of its mid-stage trial of its novel gene therapy candidate, Ixo-vec, in patients with wet age-related macular
Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Bloom Energy Corporation (NYSE:BE) rose sharply in today's pre-market trading after the company announced a strategic partnership with CoreWeave.Bloom Energy said it entered into a
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data From the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks - Efficacy: 76% of 6E10 patients were
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 50.0% and a total average
Buy Rating Affirmed for Adverum Biotechnologies Amid Promising Ixo-Vec Therapy Prospects and Undervaluation
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 51.2% and a total average return of 22.4%
Adverum Biotechnologies to Host Webcast to Review Clinical Data From the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
Express News | Adverum Biotechnologies Inc : RBC Cuts Target Price to $15 From $20
Adverum Biotechnologies Initiated at Outperform by Oppenheimer
Adverum Biotechnologies Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $25
Oppenheimer analyst Francois Brisebois initiates coverage on $Adverum Biotechnologies(ADVM.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a succes
Analysis
Price Target
No Data
